Drug Trial Radar · NCT03617731
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
662
Actual
Start
Oct 18, 2018
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- University of Heidelberg Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide/bortezomib/dexamethasone (RVd) and in lenalidomide maintenance treatment
Conditions
- Multiple Myeloma
Interventions
LenalidomideDrug
25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
BortezomibDrug
all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
DexamethasoneDrug
20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
IsatuximabDrug
10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
Primary outcomes
What the sponsor says the trial is designed to measure.
- MRD negativity after induction Treatment (comparison of arms IA and IB)Time frame: 18 weeks after start of study treatment
- Progression Free Survival (PFS) after second randomization (arms IIA and IIB)Time frame: time from 2. randomization to progression or death from any cause whichever comes first, censored after three years of maintenance therapy
Locations
72 sites in 1 country. Site status is shown where the registry gives one.
Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation
Aachen, Germany
Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin
Bad Saarow, Germany
Charité, Campus Benjamin Franklin , III. Medizinische Abteilung (Hämatologie/Onkologie)
Berlin, Germany
Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie
Berlin, Germany
HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie
Berlin, Germany
Studiengesellschaft Onkologie Bielefeld GbR
Bielefeld, Germany
Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin
Bielefeld, Germany
Medizinische Universitätsklinik, Knappschaftskrankenhaus
Bochum, Germany
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie
Bonn, Germany
Johanniter Krankenhaus Bonn
Bonn, Germany
Zentrum für ambulante Hämatologie und Onkologie (ZAHO)
Bonn, Germany
Städtisches Klinikum Braunschweig, Med. Klinik III, Hämatologie und Onkologie
Braunschweig, Germany
Klinikum Chemnitz GmbH, Innere Medizin III
Chemnitz, Germany
Uniklinik Köln, Klinik I für Innere Medizin
Cologne, Germany
Carl-Thiem-Klinikum Cottbus gGmbH, II. Medizinische Klinik
Cottbus, Germany
Onkologisches Studienzentrum Darmstadt
Darmstadt, Germany
Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie
Darmstadt, Germany
Universitätsklinikum Carl Gustav Carus Dresden, an der Technischen Universität Dresden, Medizinische Klinik und Poliklinik I
Dresden, Germany
HELIOS St. Johannes Klinik, Akademisches Krankenhaus der Heinrich-Heine-Universität Düsseldorf
Duisburg, Germany
Marien Hospital Düsseldorf GmbH, Klinik für Onkologie, Hämatologie und Palliativmedizin
Düsseldorf, Germany
Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie
Düsseldorf, Germany
Universitätsklinik Erlangen
Erlangen, Germany
St. Antonius-Hospital Eschweiler, Klinik für Hämatologie / Onkologie
Eschweiler, Germany
Universitätsklinikum Essen, Klinik für Hämatologie
Essen, Germany
Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation
Essen, Germany
Gemeinschaftspraxis Prof. Dr. Michael Kiehl und Dipl. Med. Wolfgang Stein
Frankfurt (Oder), Germany
Klinikum Frankfurt (Oder) GmbH
Frankfurt (Oder), Germany
Centrum für Hämatologie und Onkologie Bethanien
Frankfurt am Main, Germany
Agaplesion Markus Krankenhaus, Med. Klinik I
Frankfurt am Main, Germany
Krankenhaus Nordwest, Institut für Klinisch-Onkologische Forschung
Frankfurt am Main, Germany
Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II
Frankfurt am Main, Germany
Klinikum Fulda, Klinisches Studienzentrum GmbH
Fulda, Germany
Universitätsklinik der Justus-Liebig-Universität, Medizinische Klinik IV
Giessen, Germany
Katholisches Karl-Leisner-Klinikum gGmbH, Wilhelm-Anton-Hospital Goch, Klinik für Hämatologie - Onkologie
Goch, Germany
Kath. Krankenhaus Hagen gGmbH, Abt. Hämatologie/Onkologie
Hagen, Germany
Asklepios Klinik Hamburg St. Georg
Hamburg, Germany
Universitätsklinikum Hamburg Eppendorf, Zentrum für Onkologie, Studienzentrale der II. Medizinischen Klinik
Hamburg, Germany
Asklepios Klinik Hamburg Altona, II. Med. Klinik
Hamburg, Germany
Immunologisch-onkologisches MVZ am Siloah Krankenhaus
Hanover, Germany
KRH Klinikum Siloah, Klinik für Hämatologie und Onkologie
Hanover, Germany
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.